Authors
Latest:
Dr. Figlin on Treatment Strategies in Advanced RCCRobert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses treatment strategies for patients with advanced renal cell carcinoma.
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Andtbacka Discusses Next Steps With T-VEC in MelanomaRobert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.
Latest:
Dr. Den Discusses the Future of Prostate Cancer ResearchRobert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.
Latest:
Don't Get Caught Behind the MACRA CurveAlthough the MIPS and MACRA rule is preliminary and subject to change, CMS is clearly putting a lot of weight into it, and the act will be a major part of oncology practice.
Latest:
Dr. Bast on Earlier Detection of Ovarian CancerRobert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.
Latest:
Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLCRobert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non-small cell lung cancer.
Latest:
The Significance of JTCC Joining Georgetown Lombardi Cancer ConsortiumRobert C. Garrett, FACHE, chief executive officer, Hackensack Meridian Health, discusses the significance of John Theurer Cancer Center joining the Georgetown Lombardi Cancer Consortium.
Latest:
Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin KalinskyOncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Implementing Quality Standards and Personalized Approaches into OncologyRobert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.
Latest:
Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCLRobert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.
Latest:
Dr Dreicer on the Different Approaches to mCRPC ManagementRobert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.
Latest:
Dr Dreicer on the Complexities of Prostate CancerRobert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Latest:
Dr Dreicer on Managing Biochemical Failure Post-Radical Prostatectomy in Prostate CancerRobert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.
Latest:
Dr. Coleman on Findings From the AZURE Trial for Breast Cancer TreatmentRobert E. Coleman, MBBS, MD, FRCP, FRCPE, professor of Medical Oncology and head of the Academic Unit of Clinical Oncology at the University of Sheffield, discusses the safety findings from the 10-year follow-up of the adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer, which was studied in the AZURE trial.
Latest:
Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLCRobert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.
